This study aimed to assess the cost-effectiveness of TLE-CHM as an initial treatment for HER2-negative advanced G/GEJ adenocarcinoma from the perspective of the Chinese healthcare system. This evidence concerns the gene CHM and gastroesophageal junction adenocarcinoma.